Phathom Pharmaceuticals, Inc. (PHAT) News
Follow Phathom Pharmaceuticals, Inc. (PHAT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Phathom Pharmaceuticals Schedules Q3 2026 Results Call
Phathom Pharmaceuticals will report third-quarter 2026 financial results and provide a business update by webcast on Oct. 29, 2026, at 8:00 a.m. EDT.
EQUITY | Oct 19, 2026, 12:07 PM UTC
L
Phathom begins Phase 3 pHalcon-NERD-302 trial of VOQUEZNA as-needed in NERD, topline due Q1 2028
Phathom initiated patient screening for a registrational Phase 3 study of VOQUEZNA as-needed in Non—Erosive GERD, with topline results expected in Q1 2028.Key Highlights:Original SEC Filing: Phathom Pharmaceuticals, Inc.
REGULATION | Sep 29, 2026, 08:53 PM UTC
L
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. NASDAQ:PHAT, a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal dise
NEWS | Sep 29, 2026, 12:09 PM UTC
L
PHAT shares fall about 7% after Leerink starts Market Perform
Phathom Pharmaceuticals (PHAT) shares slid about 7% after Leerink Partners opened coverage with a Market Perform rating and a $10 price target, citing limited near-term upside from a crowded, price-sensitive market for i
EQUITY | Sep 09, 2026, 05:27 PM UTC
L
PHAT reflux therapy targets $2B+ peak sales on strong adoption
PHAT’s gastroesophageal reflux therapy is cited as driving rapid revenue growth and profitability, with peak sales potential exceeding $2B across specialist and primary care channels, backed by pipeline expansion.
EQUITY | Sep 09, 2026, 04:34 PM UTC
L
PHAT therapy expansion targets $2B+ peak sales on rising physician adoption
A gastroesophageal reflux therapy is driving rapid revenue growth, with peak sales potential exceeding $2B via expansion into daily and as-needed use. Physician adoption is rising on streamlined access, supported by pipe
EQUITY | Sep 09, 2026, 04:05 PM UTC
L
Phathom Pharmaceuticals initiated at Market Perform; PT set at $10
Leerink Partners initiated Phathom Pharmaceuticals with a Market Perform rating and announced a $10.00 per-share price target, per TradingView News via Benzinga.
EQUITY | Sep 09, 2026, 03:48 PM UTC
L
Phathom Pharmaceuticals to participate in upcoming investor conferences
Phathom Pharmaceuticals said members of its management team are scheduled to participate in upcoming investor conferences.
EQUITY | Sep 01, 2026, 12:07 PM UTC
L
PHAT - Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
PHAT - Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
EQUITY | Sep 01, 2026, 12:00 PM UTC
L
Phathom Pharmaceuticals Lowers FY2026 Sales Guidance from $320.000M-$345.000M to $310.000M-$325.000M vs $332.196M Est
Phathom Pharmaceuticals (NASDAQ: PHAT ) lowers FY2026 sales outlook from $320.000 million-$345.000 million to $310.000 million-$325.000 million vs $332.196 million estimate.
EARNINGS | Jul 30, 2026, 11:01 AM UTC
L
PHAT - Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
PHAT - Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
EARNINGS | Jul 30, 2026, 10:59 AM UTC